CHANTILLY, Va., Dec. 08, 2025 (GLOBE NEWSWIRE) — Parsons Corporation (NYSE:PSN), the systems integrator for the Office of Space Commerce’s (OSC) Traffic Coordination System for Space (TraCSS) program, is proud to announce that this groundbreaking advancement in space traffic coordination has been recognized with the esteemed 2025 SpaceNews Icon Award for Civil Space Achievement. This prestigious accolade underscores Parsons’ commitment to advancing safe and efficient operations in an increasingly congested orbital environment. “Receiving the SpaceNews Icon Award for Civil Space Achievement is a tremendous honor for Parsons Corporation and our Space Operations Team,” said James Johnson, senior vice president for Parsons Space Solutions Sector. “This recognition reflects the hard work of our talented teams who have been instrumental...

Patients in 200 mg BID cohort had median progression free survival of 6.2 months and median overall survival of 28.1 months, comparing favorably to results with other therapies Data supports ongoing registration Phase 3 trial in r/r PTCL, Phase 1 trial in atopic dermatitis and potential expansion into other immune and inflammatory diseases Highlights ITK inhibition novel mechanism of action affecting T cell receptor signaling and T cell differentiation Presented in an oral session at the 67th American Society of Hematology Annual Meeting & Exposition SOUTH SAN FRANCISCO, Calif., Dec. 08, 2025 (GLOBE NEWSWIRE) — Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, announced the presentation of final data from its Phase 1/1b trial of soquelitinib in patients with T cell lymphoma today in...

– 86% (32/37) CRc and 73% (27/37) CR in newly diagnosed NPM1-m AML, with 68% (17/25) of CRc responders achieving molecular MRD negativity by central NGS  – Median duration of complete response and overall survival not yet reached in newly diagnosed NPM1-m patients as of data cutoff – – 65% (31/48) ORR in R/R NPM1-m AML, 83% (19/23) ORR in venetoclax-naïve – – 41% (13/32) ORR in R/R KMT2A-r AML, 70% (7/10) ORR in venetoclax-naïve – – Triplet combination was well tolerated in both newly diagnosed and relapsed/refractory settings; addition of ziftomenib did not increase toxicity beyond that expected with venetoclax/azacitidine alone – – Ziftomenib’s broad clinical development program spans multiple front-line and relapsed/refractory regimens across NPM1-m, FLT3-m and KMT2A-r AML subtypes – – Company-sponsored registrational trials of ziftomenib...

CLN-049 monotherapy demonstrates promising efficacy, including multiple complete responses and encouraging response durability, in a heavily pretreated all-comer population of patients with R/R AML 31% CR/CRh rate observed at the highest target dose tested to date; initial dose escalation results in 45 patients demonstrate a favorable safety profile across all doses assessed CLN-049 recently granted Fast Track designation by the U.S. FDA Company to host in-person event on Monday, December 8, at 8:00 p.m. ET CAMBRIDGE, Mass., Dec. 08, 2025 (GLOBE NEWSWIRE) — Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, high-impact therapies in autoimmune diseases and cancer, today shared updated clinical data from its Phase 1 study of CLN-049, a novel, investigational...

HIAB CORPORATION, STOCK EXCHANGE RELEASE, 8 DECEMBER 2025 AT 5:00 PM (EET) Changes in Hiab Leadership Team Sanna Ahonen, EVP, Strategy and Sustainability and member of Hiab Leadership team, has decided to step down from her role. Effective immediately, her responsibilities transition to Kimberly Allan, EVP, Business Excellence. To facilitate a structured handover, Sanna will remain available upon request until 4 June 2026. “On behalf of the entire leadership team, I want to sincerely thank Sanna for her contributions to Hiab. She has played an important role in our demerger and leading our strategy and sustainability teams. I wish her every success in her future endeavours,” says Hiab’s President and CEO Scott Phillips. For further information, please contact:Birgitte Skade, Executive Vice President, Marketing and Communications,...

BASE SHELF PROSPECTUS AND PRELIMINARY PROSPECTUS SUPPLEMENT ACCESSIBLE AND FINAL PROSPECTUS SUPPLEMENT TO BE ACCESSIBLE WITHIN TWO BUSINESS DAYS ON SEDAR+ VANCOUVER, British Columbia, Dec. 08, 2025 (GLOBE NEWSWIRE) — Gold Royalty Corp. (“Gold Royalty” or the “Company”) (NYSE American: GROY) is pleased to announce that as a result of excess demand, it has agreed with National Bank Capital Markets, BMO Capital Markets, and RBC Capital Markets as joint bookrunners, on behalf of a syndicate of underwriters (collectively, the “Underwriters”) to increase the size of its previously announced bought deal financing. Gold Royalty will now issue 22,500,000 common shares of the Company (the “Common Shares”) at a price of US$4.00 per Common Share (the “Offering Price”) for aggregate gross proceeds of US$90.0 million (the “Offering”). The Company...

Not for distribution to United States newswire services or for dissemination in the United States VANCOUVER, British Columbia, Dec. 08, 2025 (GLOBE NEWSWIRE) — Miata Metals Corp. (CSE:MMET) (FSE: 8NQ) (OTCQB: MMETF) (“Miata” or the “Company”) is pleased to announce that it has closed its previously announced short form prospectus offering (the “Offering”) of common shares of the Company (“Common Shares”). The Company issued a total of 23,958,500 Common Shares at a price of $0.48 per share for gross proceeds of $11,500,080, inclusive of the full exercise of the over-allotment option. The Common Shares were offered by way of a short form prospectus dated December 3, 2025 (the “Prospectus”) filed with the securities regulatory authorities in each of the provinces of Canada, other then the province of Québec, and in such other jurisdictions...

HANGZHOU, China, Dec. 08, 2025 (GLOBE NEWSWIRE) — Jiuzi Holdings Inc. (NASDAQ: JZXN; the “Company” or “JZXN”),  a leading new energy vehicle (NEV) dealership group operating under the brand name “Jiuzi” in China is reporting that its board of directors has approved a reverse stock split (the “Reverse Stock Split”) of the Company’s ordinary shares, a par value of US$0.00195 each (the “Ordinary Shares”), at a ratio of 1-for-40, with a post-Reverse Stock Split par value of US$0.078. The Company is undertaking the Reverse Stock Split with the objective of meeting the minimum $1.00 per Ordinary Share bid requirement for maintaining the listing of the Ordinary Shares on The Nasdaq Capital Market. The Reverse Stock Split will be effective at 04:01 p.m. (ET) on Wednesday, December 10, 2025 (the “Record Date”) and the Ordinary Shares will...